Mandovra, N.P.; Vaidya, P.J.; Shah, R.S.; Nighojkar, A.S.; Chavhan, V.B.; Lohiya, A.; Leuppi, J.D.; Leuppi-Taegtmeyer, A.; Chhajed, P.N.
Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease. J. Clin. Med. 2023, 12, 6513.
https://doi.org/10.3390/jcm12206513
AMA Style
Mandovra NP, Vaidya PJ, Shah RS, Nighojkar AS, Chavhan VB, Lohiya A, Leuppi JD, Leuppi-Taegtmeyer A, Chhajed PN.
Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease. Journal of Clinical Medicine. 2023; 12(20):6513.
https://doi.org/10.3390/jcm12206513
Chicago/Turabian Style
Mandovra, Neha P., Preyas J. Vaidya, Ria S. Shah, Aishwarya S. Nighojkar, Vinod B. Chavhan, Ayush Lohiya, Joerg D. Leuppi, Anne Leuppi-Taegtmeyer, and Prashant N. Chhajed.
2023. "Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease" Journal of Clinical Medicine 12, no. 20: 6513.
https://doi.org/10.3390/jcm12206513
APA Style
Mandovra, N. P., Vaidya, P. J., Shah, R. S., Nighojkar, A. S., Chavhan, V. B., Lohiya, A., Leuppi, J. D., Leuppi-Taegtmeyer, A., & Chhajed, P. N.
(2023). Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease. Journal of Clinical Medicine, 12(20), 6513.
https://doi.org/10.3390/jcm12206513
